Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05372458
Other study ID # KY2021-007
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date December 31, 2023

Study information

Verified date May 2022
Source Huashan Hospital
Contact Donglang Jiang, MD
Phone +86-13795345740
Email dljiang16@fudan.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Alzheimer's disease (AD) is closely related to diabetes (DM). DM will aggravate the progression of AD, but the specific mechanism has not yet been clarified. Previous study found that a key pathological feature of the pancreas in patients with DM is islet amyloid polypeptide, and there is also islet amyloid polypeptide in the brain. Therefore, DM may cause cytotoxicity through the interaction between pancreatic amyloid and brain Aβ protein and further aggravate AD progress. In this study, starting with DM and AD pathological biomarkers, the amyloid PET target molecular probe 18F-AV45 will be used to monitor the dynamic changes of amyloid protein in the brain and pancreas during the development of AD. The completion of this study will provide a new view for understanding the mechanism of DM on AD cognitive dysfunction and effectively preventing and treating these two diseases.


Description:

This is a single-center, prospective, and observational study, which mainly focuses on the interaction between pancreatic amyloid and brain Aβ protein and further aggravates AD progress in China. PET imaging will be used on subjects. Previously collected patient data may also be enrolled in this study.


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years to 80 Years
Eligibility Inclusion Criteria: - Non-disease controls: 1. Age between 60 and 80 years old; gender is not limited. 2. The investigators have normal cognition and negative Aß imaging through the test. 3. Informed consent must be signed in writing by the subjects or their legal guardians and caregivers. 4. Blood routine: white blood cell count (WBC) 4~10×109/L; platelet (PLT) 100~300×109/L; hemoglobin (HB) 120~160 g/L; renal function: serum creatinine less than or equal to Upper limit of normal range; liver function: bilirubin, AST (SGOT)/ALT (SGPT) less than or equal to the upper limit of normal range; electrocardiogram: no significant abnormality. 5. Willingness and ability to cooperate with all projects of this research. AD patients/DM patients: 1. Age between 60 and 80 years old; gender is not limited. 2. The diagnosis of AD was based on the 2011 National Association on Aging and Alzheimer's Disease (NIA-AA) diagnostic criteria for possible AD dementia. The diagnostic criteria for diabetes were based on the 1999 World Health Organization (WHO) diagnostic criteria for diabetes. 3. Brain MRI supports the diagnosis of AD, and there is no evidence of other neurological diseases. 4. No neurological disease, major chronic disease, malignant tumor or acute infectious disease has been confirmed by the investigator. 5. An informed consent form must be signed in writing by the subjects or their legal guardians and caregivers. 6. Blood routine: white blood cell count (WBC) 4~10×109/L; platelet (PLT) 100~300×109/L; hemoglobin (HB) 120~160 g/L; renal function: serum creatinine less than or equal to Upper limit of normal range; function: bilirubin, AST (SGOT)/ALT (SGPT) less than or equal to the upper limit of normal range; electrocardiogram: no significant abnormality. 7. Willingness and ability to cooperate with all projects of this research. Exclusion Criteria: - Subjects meeting any of the following criteria will be excluded from the study: 1. Suffering from other serious neurological diseases, or gastrointestinal, cardiovascular, liver, kidney, blood system, tumor endocrine, respiratory system, immune deficiency and other serious diseases. 2. Candidate subjects have contraindications to PET/CT scanning. Those who cannot accept repeated intravenous injections; those who may be allergic to drugs and their components (including a history of severe allergy or allergic reactions, especially those who are allergic to the tested drugs); phobia of tightness. 3. In the past year, in addition to participating in the expected radiation exposure of this clinical study, have participated in other research programs or clinical care, resulting in radiation exposure exceeding the effective dose of 50 mSv. 4. Drug or alcohol abuse for at least 1 month. 5. The venous condition is poor and cannot tolerate repeated venipuncture. 6. The candidate subject has received major surgery within the past 3 months; received experimental drug or device treatment (with unclear effect or safety) within 1 month 7. The candidate subjects have any clinical conditions that the host of this study believes that this preparation may cause or have potential harm.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Huashan Hospital Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Huashan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complete PET imaging Assessment of PET/CT imaging to detect abeta in patients with AD and DM 50mins from time of injection
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04520308 - An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis Phase 4
Recruiting NCT06155201 - Development and Application of Intelligent Diagnosis and Treatment Norms for Children and Adolescents With Mental Disorders N/A
Recruiting NCT06335836 - The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)
Active, not recruiting NCT02380573 - Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease Phase 2
Terminated NCT01733355 - A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807 Phase 0
Completed NCT03932916 - Safety and Pharmacokinetic of Donepezil Pamoate in Healthy Subjects Phase 1
Completed NCT01190904 - Hormones and Sexual Function Predict Outcomes in Revascularized Men With Diabetes N/A
Enrolling by invitation NCT06245031 - Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015) N/A
Terminated NCT05984784 - A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) Phase 1/Phase 2
Completed NCT02273895 - The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study N/A